- 作者：J.M. Rintala ; J. Savikko ; S.E. Rintala ; E. von Willebr
- 刊名：Transplantation Proceedings
- 出版年：2006
- 出版时间：October 2006
- 年：2006
- 卷：38
- 期：8
- 页码：2719-2721
- 全文大小：47 K
Acute rejection is the single most important risk factor for the development of subsequent chronic allograft nephropathy (CAN). Both platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF-β) are major mitogens mediating mesenchymal cell proliferation and epithelial to mesenchymal cell transition. Early posttransplant induction of these growth factors may start molecular mechanisms leading to CAN. A new promising immunosuppressive drug, FK778, is an analogue of the active metabolite of leflunamide, which inhibits de novo pyrimidine biosynthesis. Herein we investigated the effect of FK778 on acute rejection and on the expression of PDGF and TGF-β both alone and in combination with cyclosporine (CsA) or tacrolimus (Tac).
Methods
Kidney transplantations were performed from Dark Agouti (DA) to Wistar-Furth (WF) rats with syngeneic controls between DA rats. No immunosuppression was given to syngeneic grafts. Allografts were immunosuppressed with FK778 alone or in combination with CsA or Tac. Grafts were harvested on day 5 for histology and immunohistochemistry (PDGF-A, -B, PDGFR-α, -β, TGF-β1, and TGF-βR1).
Results
FK778 ameliorated the inflammatory response and reduced PDGF and TGF-β expression in a dose-dependent manner. It also showed synergy with calcineurin inhibitors, an effect that was stronger with Tac than with CsA.
Conclusions
Our results indicated that FK778 decreased PDGF and TGF-β expression early in acute rejection, suggesting it to be a promising therapy for CAN.